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 Azole Antifungal Agents To Treat the Human Pathogens
Acanthamoeba castellanii and Acanthamoeba polyphaga through
Inhibition of Sterol 14-Demethylase (CYP51)
David C. Lamb,a Andrew G. S. Warrilow,a Nicola J. Rolley,a Josie E. Parker,a W. David Nes,b Stephen N. Smith,a Diane E. Kelly,a
Steven L. Kellya
Centre for Cytochrome P450 Biodiversity, Institute of Life Science, College of Medicine, Swansea University, Swansea, Wales, United Kingdoma; Center for Chemical
Biology, Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, USAb
In this study, we investigate the amebicidal activities of the pharmaceutical triazole CYP51 inhibitors fluconazole, itraconazole,
and voriconazole against Acanthamoeba castellanii and Acanthamoeba polyphaga and assess their potential as therapeutic
agents against Acanthamoeba infections in humans. Amebicidal activities of the triazoles were assessed by in vitrominimum
inhibition concentration (MIC) determinations using trophozoites of A. castellanii and A. polyphaga. In addition, triazole effec-
tiveness was assessed by ligand binding studies and inhibition of CYP51 activity of purified A. castellanii CYP51 (AcCYP51) that
was heterologously expressed in Escherichia coli. Itraconazole and voriconazole bound tightly to AcCYP51 (dissociation con-
stant [Kd] of 10 and 13 nM), whereas fluconazole bound weakly (Kd of 2,137 nM). Both itraconazole and voriconazole were con-
firmed to be strong inhibitors of AcCYP51 activity (50% inhibitory concentrations [IC50] of 0.23 and 0.39M), whereas inhibi-
tion by fluconazole was weak (IC50, 30M). However, itraconazole was 8- to 16-fold less effective (MIC, 16 mg/liter) at
inhibiting A. polyphaga and A. castellanii cell proliferation than voriconazole (MIC, 1 to 2 mg/liter), while fluconazole did not
inhibit Acanthamoeba cell division (MIC,>64 mg/liter) in vitro. Voriconazole was an effective inhibitor of trophozoite prolifer-
ation for A. castellanii and A. polyphaga; therefore, it should be evaluated in trials versus itraconazole for controlling Acan-
thamoeba infections.
Acanthamoeba is an opportunistic protist pathogen that isubiquitously distributed in the environment, being present in
rivers, lakes, seawater, air, and soils, as well as in domestic envi-
ronments, such as heating and air-conditioning systems, swim-
ming pools, aquariums, plants, and jacuzzis (1). Acanthamoeba
species are the causative agents of cutaneous lesions, sinus and
lung infections, amoebic keratitis of the cornea (AK), and amoe-
bic granulomatous encephalitis (AGE) (1–3). Acanthamoeba has
two stages in its life cycle: a motile vegetative trophozoite stage of
feeding and reproduction and a dormant cyst stage that occurs
when environmental conditions are harsh; this stage confers resis-
tance against extreme temperature, desiccation, UV radiation,
and several antiseptic chemicals (1, 4). Therefore, eradication of
Acanthamoeba cysts is essential in effective antiacanthamoeba
therapies.
Several species of Acanthamoeba (including A. castellanii and
A. polyphaga) are known to cause AGE, primarily among immu-
nocompromised patients (1). AGE is a rare infection but is
nearly always fatal and involves the protist parasite crossing the
blood-brain barrier to infect the brain and central nervous sys-
tem (CNS), resulting in neuronal and brain damage. Routes of
entry include the lower respiratory tract and skin lesions, with
infections of the skin and respiratory system lasting several
months, followed by infection of the CNS, resulting in death in
days to weeks (3, 5–8).
A. castellanii and A. polyphaga are the most common Acan-
thamoeba subspecies to cause AK in immunocompetent indi-
viduals (9), an infection of the cornea that can lead to blind-
ness. Up to 93% of reported AK cases are associated with
contact lens usage (10, 11). Infection is usually a result of poor
hygiene during storage and handling of contact lenses (12). In
non-lens users, AK is associated with trauma and exposure to
contaminated water or soil and is prominent among agricul-
tural workers (13). Generally only one eye is affected, with
reported cases of bilateral keratitis being rare (1, 14). AK is an
emerging disease, with reported cases increasing year upon
year, mainly due to increased contact lens usage, better diag-
nosis, and awareness (13). The number of AK cases in the 1980s
and early 1990s was typically one to two cases per million con-
tact lens wearers. By 2000 the incidence of AK had increased to
17 to 70 cases per million contact lens wearers (country depen-
dent) (12), who presently number ca. 120 million worldwide.
AK often is difficult to treat, with early detection followed by
aggressive treatment being essential for successful outcomes
(15). The recommended cysticidal treatment is the use of a
biguanide (0.02% polyhexamethylene biguanide or 0.02%
chlorhexidine digluconate) in conjunction with a diamidine
(0.1% propamidine isethionate or 0.1% hexamidine). If coin-
fection with bacteria is found, additional antibiotics, such as
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neomycin or chloramphenicol, also is recommended (3).
Combined topical application of 1% miconazole and 1%
propamidine, or oral itraconazole together with topically applied
0.1% miconazole and ketoconazole, has stopped the progress of
AK (1, 16). Voriconazole also has been used successfully both
topically and systemically to treat AK (1, 17, 18). Recent case re-
ports have pointed toward triazoles as an adjunct to biguanide and
diamidine therapy, with voriconazole proving effective either ap-
plied topically or taken orally (19, 20). However, extended treat-
ment duration was required in order to prevent relapse. Most
recently, Acanthamoeba infection has been linked immunologi-
cally with multiple sclerosis pathogenesis (21, 22). Therefore, the
effective control of Acanthamoeba before infection spreads to the
central nervous system may prove beneficial to a far broader range
of patients than first thought.
In this study, we cloned a CYP51 homologous gene fromAcan-
thamoeba castellanii into Escherichia coli and expressed and puri-
fied the recombinant protein in an active state where its activity
was confirmed. In addition, we also characterized the effectiveness
of fluconazole, itraconazole, and voriconazole at inhibitingA. cas-
tellanii CYP51 activity and in vitro proliferation of Acanthamoeba
castellanii and Acanthamoeba polyphaga.
MATERIALS AND METHODS
Construction of the pCWori:AcCYP51 expression vector. The Acan-
thamoeba castellanii CYP51 gene (AcCYP51; UniProtKB accession num-
ber L8GJB3) was synthesized by Eurofins MWG Operon (Ebersberg, Ger-
many), incorporating an NdeI restriction site at the 5= end and a HindIII
restriction site at the 3= end of the gene cloned into the pUC57 plasmid. In
addition, the first eight amino acids were changed to MALLLAVF (23),
and a six-histidine extension (CATCACCATCACCATCAC) was inserted
immediately before the stop codon to facilitate protein purification by
Ni2-nitrilotriacetic acid (NTA) agarose affinity chromatography. The
AcCYP51 gene was excised by NdeI/HindIII restriction digestion followed
by cloning into the pCWori expression vector using Roche T4 DNA
ligase. Gene integrity was confirmed by DNA sequencing.
Heterologous expression in E. coli and isolation of recombinant
AcCYP51 protein. The pCWori:AcCYP51 construct was transformed
into competent DH5 E. coli cells, and transformants were selected using
0.1 mg/ml ampicillin. Cells were grown in terrific broth (2.4% yeast ex-
tract, 1.2% tryptone, 0.1 M potassium phosphate, pH 7.5, 0.1% glycerol)
containing 0.1 mg/ml ampicillin for 7 h at 37°C and 200 rpm. Expression
was induced by the addition of isopropyl--D-thiogalactopyranoside
(IPTG) (1 mM) and 5-aminolevulenic acid (1 mM), followed by incuba-
tion at 27°C and 160 rpm for 18 h. Protein isolation was according to the
method of Arase et al. (24). The solubilized AcCYP51 protein was purified
by Ni2-NTA agarose affinity chromatography as previously described
(25), followed by dialysis against 5 liters of 20 mM potassium phosphate
(pH 7.5) and 10% glycerol. Ni2-NTA agarose-purified AcCYP51 was
used for all subsequent spectral and 50% inhibitory concentration (IC50)
determinations. Protein purity was assessed by SDS-polyacrylamide gel
electrophoresis, followed by staining with Coomassie brilliant blue R-250.
AcCYP51 spectral determinations. Cytochrome P450 concentration
was determined by reduced carbon monoxide difference spectra (26),
using an extinction coefficient of 91 mM1 cm1 (27), and from the
absolute spectrum (600 to 350 nm) (25). Azole ligand binding determi-
nations were performed as previously described (28) using quartz split
cuvettes (light path, 4.5 mm) and stock 1, 0.5, 0.2, and 0.1 mg/ml solutions
of fluconazole, itraconazole, and voriconazole in dimethyl sulfoxide.
Azole antifungals were progressively titrated against 2M AcCYP51 in 0.1
M Tris-HCl (pH 8.1) and 25% glycerol at 22°C, with equivalent volumes
of dimethyl sulfoxide also being added to the AcCYP51-containing com-
partment of the reference cuvette. The absorbance difference spectra be-
tween 500 and 350 nm were determined after each incremental addition
of azole with binding saturation curves constructed from A428-412
against azole concentration. The dissociation constant of the enzyme-
azole complex (Kd) for each azole was determined by nonlinear regression
(Levenberg-Marquardt algorithm) using a rearrangement of the Morri-
son equation for tight ligand binding (29, 30). All spectral determinations
were performed in triplicate. AcCYP51 was demonstrated to be active by
measuring the 14-demethylation of lanosterol, eburicol, and obtusifo-
liol using the CYP51 reconstitution assay described below. The chemical
structures of the azole antifungals and 14-methylated sterol substrates
used in this study are shown in Fig. 1.
CYP51 reconstitution assay system. IC50 determinations were per-
formed using the CYP51 reconstitution assay system (500-l final reac-
tion volume) previously described (31), containing 0.6M AcCYP51, 1.8
M Aspergillus fumigatus cytochrome P450 reductase (AfCPR1; Uni-
ProtKB accession number Q4WM67), 50M obtusifoliol, 50M dilauryl-
phosphatidylcholine, 4% (2-hydroxypropyl)--cyclodextrin (HPCD),
0.4 mg/ml isocitrate dehydrogenase, 25 mM trisodium isocitrate, 50 mM
NaCl, 5 mM MgCl2, and 40 mM morpholinepropanesulfonic acid
(MOPS; pH7.2). Azole antifungal agents were added in 2.5l dimethyl
sulfoxide, followed by 10 min of incubation at 30°C prior to assay initia-
tion with 4 mM -NADPH-Na4. Samples then were shaken for 30 min at
30°C. In addition, trial AcCYP51 assays also were performed using 50M
lanosterol and 50 M eburicol as substrates. Sterol metabolites were re-
covered by extraction with ethyl acetate, followed by derivatization with
N,O-bis(trimethylsilyl)trifluoroacetamide and tetramethylsilane in pyri-
dine prior to analysis by gas chromatography mass spectrometry (32).
IC50 in this study is defined as the inhibitor concentration required caus-
ing 50% inhibition of CYP51 activity under the stated assay conditions.
Azole MICs with Acanthamoeba species. Acanthamoeba polyphaga
(ATCC 30461) and Acanthamoeba castellani (ATCC 50491) were kept as
continuous cultures in ATCC 712 media at 28°C. Azole susceptibility
assays were performed in 96-well microtiter plates using an adaptation of
the resazurin cell respiration assay (33, 34). Trophozoites were grown
axenically in ATCC 712 media for 48 h at 28°C prior to dilution to 5	 104
trophozoites/ml with ATCC 712 media. Serial 100	 stock azole antifun-
gal agent dilutions were prepared in dimethyl sulfoxide of 6.4, 3.2, 1.6, 0.8,
0.4, 0.2, 0.1, 0.05, 0.025, 0.0125, 0.0625, and 0.03125 mg/ml. These solu-
tions initially were diluted 10-fold using ATCC 712 medium, of which 20
l was added directly to culture plate wells containing 180l trophozoite
inoculum (0.9	 104 cells) to achieve final azole concentrations of 64, 32,
16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.0625, and 0.03125 g/ml. Control wells
containing 1% dimethyl sulfoxide and trophozoites also were prepared.
The microtiter plates were incubated at 28°C for 48 h, after which 30l of
0.02% aqueous resazurin dye was added and the microtiter plates incu-
bated for a further 48 h at 28°C. A color change from purple to pink
indicated the presence of respiring cells. MIC determinations were per-
formed in triplicate and scored manually and are defined here as the
lowest azole concentration at which cell respiration remained completely
inhibited.
Data analysis. Curve fitting of ligand binding data was performed using
the computer program ProFit 6.1.12 (QuantumSoft, Zurich, Switzerland).
Spectral determinations were made using quartz semi-micro cuvettes with a
Hitachi U-3310 UV-visible spectrophotometer (San Jose, California).
The N-terminal membrane anchor region of AcCYP51 was predicted
using the TargetP, version 1.1 (http://www.cbs.dtu.dk/services/TargetP/),
software. Subcellular location was predicted using WoLF PSORT
(http://www.genscript.com/psort/wolf_psort.html) software. Phyloge-
netic analyses were performed by comparing the AcCYP51 amino acid
sequence (UniProtKB accession number L8GJB3) to selected fungal,
plant, and animal CYP51 proteins from the UniProtKB database (http:
/ /www.uniprot .org/he lp/uniprotkb) us ing BLAST2 (ht tp :
//blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE
BlastSearch&
PROG_DEF
blastn&BLAST_PROG_DEF
megaBlast&BLAST_SPEC

blast2seq) and ClustalX version 1.81 (http://www.clustal.org/) se-
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quence alignment software with a phylogenetic tree produced from the
ClustalX-generated Phylip-dnd file using TreeviewX (https://code.google
.com/p/treeviewx/) software. NCBI-BLASTP analysis (http://www.ncbi
.nlm.nih.gov/blast/Blast.cgi?CMD
Web&PAGE_TYPE
BlastHome) also
was performed using the AcCYP51 sequence as the template.
The fungal CYP51 sequences used were Cryptococcus neoformans var.
neoformans (Q5KQ65), Candida albicans (P10613), Malassezia globosa
(A8Q3I7), Trichophyton rubrum (F2SHH3), Schizosaccharomyces pombe
(Q09736), Ustilago maydis (P49602), Saccharomyces cerevisiae (P10614),
Phanerochaete chrysosporium (B6DX27), Botryotinia fuckeliana (Q9P428),
Mycosphaerella graminicola (Q5XWE5), Penicillium italicum (Q12664),
Aspergillus fumigatusCYP51A (Q4WNT5),Aspergillus fumigatusCYP51B
(Q96W81), andCandida glabrata (P50859). The animal CYP51 sequences
used were Homo sapiens (Q16850), Danio rerio (Q1JPY5), Xenopus tropi-
calis (Q28CJ0), Rattus norvegicus (Q64654), and Sus scrofa (O46420). The
plant CYP51 sequences used were Cucumis sativus (UPI0002B48861),
Solanum lycopersicum (D9J0A9), Oryza sativa (Q2R3E2), Arabidopsis
thaliana (Q9SAA9), Solanum chacoense (Q673E9), Populus trichocarpa
(B9GMU7), and Sorghum bicolor (P93846). Other CYP51 sequences
used were Aphanomyces euteiches (B2ZWE1), Saprolegnia parasitica
(BROAD Institute accession number SPRG_09493.2), Galdieria sulfuraria
(M2X6V3),Trypanosoma cruzi (Q7Z1V1),Trypanosoma brucei (Q385E8),
and Leishmania infantum (A2TEF2).
Chemicals.All chemicals, unless otherwise stated, were obtained from
Sigma Chemical Company (Poole, United Kingdom). Voriconazole was
supplied by Discovery Fine Chemicals (Bournemouth, United Kingdom).
Growth media, sodium ampicillin, IPTG, and 5-aminolevulenic acid were
obtained from Foremedium Ltd. (Hunstanton, United Kingdom). Ni2-
NTA agarose affinity chromatography matrix was obtained from Qiagen
(Crawley, United Kingdom).
RESULTS
Analysis ofAcCYP51protein sequence.TargetP predicted that the
AcCYP51 N-terminal membrane anchor consists of the first 34
amino acid residues, while WoLF PSORT predicted AcCYP51 would
be located in the endoplasmic reticulum. This agrees with the obser-
vation that eukaryotic CYP51 proteins are associated with the mem-
branes of the endoplasmic reticulum (35). Alignment of AcCYP51
against other eukaryotic CYP51 proteins confirmed that all 23 con-
served amino acid residues previously identified for CYP51 proteins
(36) were present in AcCYP51. The resultant phylogenetic tree (Fig.
2) showed AcCYP51 shared greatest sequence identity with the ther-
moacidophilic unicellular red alga G. sulfuraria CYP51 (54%). In
addition, AcCYP51 shared 44 to 47% sequence identity with higher
plant CYP51 enzymes (47% with cucumber CYP51), 45% sequence
identity with the oomycete CYP51 proteins from S. parasitica andA.
euteiches, 37 to 39% identity with animal CYP51 proteins (38% iden-
tity with human CYP51), 36 to 38% sequence identity with the
trypanosomal CYP51 proteins, and 31 to 35% sequence identity with
the fungal CYP51 proteins (31% identity withC. albicansCYP51 and
35% identity with A. fumigatus CYP51A). The top 12 NCBI-
BLASTP hits against AcCYP51 were cytochrome P450 proteins
from Galdieria sulfuraria (sequence identity 54%; http://www
.uniprot.org/uniprot/M2X6V3), Guillardia theta CCMP2712
(XP_005826589.1; 53%), Micromonas pusilla CCMP1545
(XP_003061538.1; 50%), Micromonas sp. strain RCC299
(XP_002509219.1; 51%), Ostreococcus lucimarinus CCE9901
(XP_001420297.1; 50%), Bathycoccus prasinos (XP_007509480.1;
50%), Helicosporidium sp. strain ATCC 50920 (KDD76879.1;
50%), Volvox carteri f. nagariensis (XP_002946369.1; 49%), Chla-
mydomonas reinhardtii (XP_001701788.1; 48%), Geum rivale
(CCH26420.1; 46%), Physcomitrella patens (XP_001769413.1;
46%), andCyanidioschyzonmerolae strain 10D (XP_005538940.1;
50%), with cucumber CYP51 (XP_004152160.1) being the 22nd
closest match to AcCYP51.
Expression and purification of AcCYP51. The yield of Ac-
CYP51 was 50  20 nmol/liter E. coli culture as determined by
absolute spectroscopy (25) after purification by Ni2-NTA aga-
rose chromatography. SDS-polyacrylamide gel electrophoresis
FIG 1 Azole antifungal agents and 14-methylated sterols used in this study. The chemical structures of fluconazole (molecular weight [MW], 306), itraconazole
(MW, 706), voriconazole (MW, 349), obtusifoliol (MW, 426), lanosterol (MW, 426), and eburicol (MW, 440) are shown.
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confirmed the purity of the Ni2-NTA agarose-eluted AcCYP51
protein to be greater than 90% when assessed by Coomassie bril-
liant blue R-250 staining intensity, with an apparent molecular
weight of50,000 2,000, which was close to the predicted value
of 56,585 and included the six-histidine C-terminal extension.
Spectral properties of recombinant AcCYP51 protein. The
absolute spectrum of AcCYP51 (Fig. 3A) was typical for a ferric
cytochrome P450 enzyme predominantly in the low-spin state
(25, 37), with , , and Soret () spectral bands at 568, 536, and
415 nm, respectively. However, the  spectral band (360 nm)
appeared merged with the tail end of the Soret peak. Reduced
carbon monoxide difference spectra (Fig. 3B) produced the char-
acteristic red-shifted Soret peak at 448 nm typical of ferrous cyto-
chrome P450 enzymes complexed with CO (26, 27). However, the
reduced CO adduct at 448 nm was relatively slow in forming, with
a half-life (t1/2) of 3.7 0.2 min. In addition, the presence of the
inactive P-420 complex absorbance at 422 nm only slowly dimin-
ished with time.
Type II binding spectra were observed between 2 M Ac-
CYP51 and fluconazole, itraconazole, and voriconazole (Fig. 4),
yielding a peak at 428 nm and a trough at 412 nm. Type II
binding spectra arise from the triazole N-4 nitrogen coordinating
as the sixth ligand with the heme iron (38) to form the low-spin
CYP51-azole complex, resulting in a red shift of the heme Soret
peak. Tight binding normally is observed where theKd for a ligand
is similar to or lower than the concentration of the protein present
(39). Azole saturation curves (Fig. 4) confirmed itraconazole and
voriconazole bound tightly to AcCYP51 with apparent Kd values
of 10.4  1.2 and 13.4  3.8 nM. However, fluconazole binding
appeared to be 160- to 205-fold weaker (Kd of 2,137  645 nM).
Therefore, the azole ligand binding studies predict that both itra-
conazole and voriconazole would strongly inhibit AcCYP51 activ-
ity while fluconazole would be a weak AcCYP51 inhibitor.
Azole inhibition of AcCYP51 sterol 14-demethylase activ-
ity. Obtusifoliol, lanosterol, and eburicol all were 14-demethyl-
ated in the CYP51 reconstitution assay using purified AcCYP51
protein and AfCPR1 as the redox partner with turnover numbers
of 0.474, 0.101, and 0.142/min, respectively. This confirmed the
CYP51 enzyme function of the protein and that AcCYP51 had
been isolated in a fully functional form. IC50 determinations using
0.6 M AcCYP51 (Fig. 5) and obtusifoliol as the substrate con-
firmed that both itraconazole and voriconazole strongly inhibited
AcCYP51 activity with IC50s of 0.23 and 0.39 M. The IC50 for a
tight binding azole that cannot be displaced by substrate would be
half the CYP51 concentration (0.30M) observed for itracona-
zole and voriconazole. In contrast, fluconazole inhibition of Ac-
CYP51 was poor (IC50 of 30 M), in keeping with the weaker
ligand binding observed. These results confirm the predictions
made from the azole ligand binding studies and suggest that both
itraconazole and voriconazole would be strong inhibitors ofAcan-
thamoeba proliferation.
Inhibition ofAcanthamoeba proliferation. MIC studies using
A. polyphaga and A. castellani trophozoites (Table 1) confirmed the
ineffectiveness of fluconazole at inhibiting cell proliferation ofAcan-
thamoeba with MIC values greater than 64 mg/liter. Surprisingly,
itraconazole was a relatively poor inhibitor of Acanthamoeba cell
division with MIC values of 16 mg/liter. Only voriconazole effec-
tively inhibitedAcanthamoeba proliferation in vitrowith MIC val-
ues of 1 to 2 mg/liter, confirming voriconazole as an effective
anti-amebic agent against trophozoites.
FIG 2 Phylogenetic tree of CYP51 enzymes. A phylogenetic tree of selected
eukaryotic CYP51 proteins, including members from the fungus, plant, and
animal kingdoms, in addition to trypanosomal and oomycete CYP51 proteins,
was constructed using ClustalX version 1.81 (http://www.clustal.org/) and
TreeViewX (https://code.google.com/p/treeviewx/). The individual CYP51 se-
quences used to construct the phylogenetic tree are detailed in Materials and
Methods. Species names have been left nonitalicized for clarity.
FIG 3 Spectral properties of 4 M AcCYP51. The absolute oxidized absorp-
tion spectrum between 600 and 350 nm (light path, 4.5 mm) (A), in addition to
the reduced carbon monoxide difference spectra between 500 and 400 nm at
sequential 45-s intervals (light path, 10 mm) (B), is shown.
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DISCUSSION
Phylogenetic analysis of CYP51 amino acid sequences suggested
that Acanthamoeba castellanii was more closely related to algae
and protists and then plants than higher animals. This was sup-
ported by the NCBI-BLASTP results. The relatively low sequence
identity (31 to 35%) of AcCYP51 with fungal CYP51 enzymes
suggests that existing clinical azole antifungal drugs are not so
efficacious againstAcanthamoeba infections. The higher AcCYP51
reaction rate observed with obtusifoliol is in keeping with obtusi-
foliol being the most abundant in vivo CYP51 substrate in Acan-
thamoeba polyphaga (40), although substrate specificity was not
absolute, as has been observed in Trypanosoma brucei CYP51 (41)
and plant CYP51 enzymes (42, 43). The substrate specificity of
AcCYP51 was broader than that observed withTrypanosoma cruzi
CYP51 (44) and Leishmania infantum CYP51 (45).
Azole binding studies suggested fluconazole (Kd of 2,137 nM)
would be a poor inhibitor of AcCYP51 activity, while itraconazole
and voriconazole (Kd of 10 and 13 nM) would be strong AcCYP51
inhibitors. Itraconazole and voriconazole previously gave simi-
larly low Kd values with Candida albicans CYP51 (46). This was
confirmed by azole IC50 determinations using the CYP51 recon-
stitution assay system (Fig. 5). Previously the affinities of human
CYP51 for voriconazole and itraconazole were determined to be
2,290 and 92 to 131 nM, respectively (46). Therefore, the selectiv-
ity for AcCYP51 over the human homolog using voriconazole and
itraconazole were 170- and 10-fold based on the measured Kd
value. In comparison, selectivity for C. albicans CYP51 over the
human homolog was 230- and 6-fold for voriconazole and itra-
conazole (46). This suggested voriconazole would be an effective
inhibitor of Acanthamoeba infections in humans due to the high
selectivity for the pathogen CYP51 over the host homolog,
whereas itraconazole would be less effective. This was borne out
during Acanthamoeba MIC determinations where only voricona-
zole proved effective as an inhibitor of Acanthamoeba prolifera-
tion in vitro with a MIC value 8- to 16-fold more potent than that
of itraconazole (Table 1). The relatively poor performance of itra-
conazole againstAcanthamoebamay be due in part to poor uptake
of the drug into the cells, as itraconazole is a bulky molecule with
a long hydrophobic tail compared to the relatively compact vori-
conazole molecule. MIC values achieved with voriconazole
against C. albicans were 24- to 375-fold lower (strain dependent)
than those for the Acanthamoeba species used in this study (47),
suggesting higher doses of triazoles will be required to be clinically
effective against Acanthamoeba infections than those presently
used to treat C. albicans infections. However, triazoles have rela-
tively low toxicity and fewer side effects in patients than alterna-
tives such as amphotericin B and can be safely tolerated at higher
doses, especially in topical applications. Further investigations are
required into the azole uptake preferences of live Acanthamoeba
trophozoites to optimize clinical effectiveness.
The widespread occurrence of AK (1–3, 10–14) and the relative
difficulty in treating the condition with prolonged use of bigua-
FIG 4 Azole binding to AcCYP51. Type II difference spectra were obtained by
progressive titration of 2 M AcCYP51 with fluconazole, itraconazole, and
voriconazole using 4.5-mm-light-path quartz semi-micro cuvettes. Azole sat-
uration curves for AcCYP51 were constructed from the change in absorbance
(A428-412) against fluconazole (filled circles), itraconazole (hollow circles),
and voriconazole (bullets) concentrations using a rearrangement of the Mor-
rison equation (29, 30) for the tight ligand binding.
FIG 5 Azole IC50 determinations for AcCYP51. IC50s were determined for
fluconazole (filled circles), itraconazole (hollow circles), and voriconazole
(bullets). The CYP51 reconstitution assays contained 0.6 M AcCYP51 and
1.8M AfCPR1 using 50M obtusifoliol as the substrate. Relative velocities of
1.00 corresponded to actual velocities of 0.474 0.025/min. The mean values
of two replicates are shown along with the associated standard deviation bars.
TABLE 1 MICs for azole antifungal agents against A. polyphaga and
A. castellanii trophozoites
Azole antifungal
MIC (mg/liter) against:
A. polyphaga A. castellanii
Fluconazole 64 64
Itraconazole 16 16
Voriconazole 1-2a 1-2a
a These MICs were between 1 and 2 mg/liter.
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nides and diamidines (15) suggests a role for triazole pharmaceu-
ticals as useful therapeutic adjuncts to conventional AK treat-
ments, especially where secondary yeast/fungal infection is
suspected. However, the use of triazole drugs to combat AGE re-
mains limited, because presently there are no recommended treat-
ments as AGE is normally diagnosed postmortem (3), although
triazoles, when used in combination with sulfadiazine, penta-
midine isethionate, amphotericin B, azithromycin, or rifampin,
may be effective if early diagnosis was possible (3). Voriconazole is
a strong candidate for the treatment of Acanthamoeba infections
in humans, especially AK, as it inhibits the proliferation of tropho-
zoites and benefits from being easily administered either orally as
tablets or topically in eye drops. Already some positive case studies
and microbiological sensitivity studies have supported this con-
clusion (1, 16–20), and our study underpins this at the biochem-
ical level. The voriconazole chemical scaffold also could be mod-
ified to create a new range of azole therapeutics that have increased
effectiveness/potency against Acanthamoeba species, and our
work outlines methods by which this can be taken forward.
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